Registration Number
0221U105891,
(0120U104095)
, R & D reports
Title
Study of coronavirus SARS-CoV-2 protein immunogenic properties as a basis for COVID19 vaccine development.
popup.stage_title
Одержання рекомбінантних протеїнів SARS-CoV-2 та злитих кон’югатів, вивчення їх імуногенності при використанні різних ад’ювантів під час імунізації мишей.
Head
Kolybo Denys V., Доктор біологічних наук
Registration Date
07-09-2021
Organization
Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine
popup.description1
The aim of the project is to study the immunogenic properties of recombinant SARS-CoV-2 coronavirus proteins and their conjugates with recombinant highly immunogenic carriers capable of active transport of proteins into cells using different adjuvants for immunization, as well as to develop the optimal composition of COVID19 vaccine and to conduct preclinical studies of vaccine prototype.
popup.description2
Recombinant coronavirus SARS-CoV-2 proteins: nucleocapsid N-protein, receptor-binding domain (RBD) of S-protein and fused conjugates of RBD with carriers (diphtheria toxoid CRM197 and green fluorescent protein eGFP) were obtained. In addition, immunogenicity of recombinant SARS-CoV-2 proteins and RBD–CRM197 fused conjugate, as well as characteristics of immune cell response when using aluminum hydroxide as adjuvant for immunization of mice were studied. It has been shown that the most immunogenic is N protein, and the least immunogenic is S protein RBD probably due to its low molecular weight. It was found that N protein, in contrast to the RBD, stimulates the expression increasing of in mouse splenic cells to increase the of IFN-gamma and to a lesser extent IL12b and IL-4, which indicates the activation of primarily cellular immune response.
Product Description
popup.authors
Horbаtiuk Oksаnа B.
Guzyk Mykhailo M.
Komisarenko Serhii V.
Korchynskiy Oleksandr H.
Krynina Olha I.
Romaniuk Svitlana I.
Siromolot Andrii A.
popup.nrat_date
2021-09-07
